Galinpepimut-S Immunotherapy Has Preliminary Efficacy in Acute Myeloid Leukemia
Among patients with acute myeloid leukemia (AML) in remission following second-line salvage therapy, the immunotherapeutic agent galinpepimut-S (GPS) demonstrated preliminary signals of efficacy and specific T-Cell immune responses in the pivotal phase 3 …